NASDAQ:STRR

Star Equity Competitors

$3.19
-0.11 (-3.33 %)
(As of 04/14/2021 03:59 PM ET)
Add
Compare
Today's Range
$3.19
Now: $3.19
$3.33
50-Day Range
$2.72
MA: $3.26
$4.18
52-Week Range
$1.99
Now: $3.19
$5.40
Volume2,070 shs
Average Volume320,168 shs
Market Capitalization$15.70 million
P/E RatioN/A
Dividend YieldN/A
Beta0.24

Competitors

Star Equity (NASDAQ:STRR) Vs. MDT, VAR, MASI, LIVN, CNMD, and INMD

Should you be buying STRR stock or one of its competitors? Companies in the industry of "electromedical equipment" are considered alternatives and competitors to Star Equity, including Medtronic (MDT), Varian Medical Systems (VAR), Masimo (MASI), LivaNova (LIVN), CONMED (CNMD), and InMode (INMD).

Medtronic (NYSE:MDT) and Star Equity (NASDAQ:STRR) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, profitability, institutional ownership, valuation, earnings, analyst recommendations and dividends.

Profitability

This table compares Medtronic and Star Equity's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Medtronic12.69%9.71%5.30%
Star Equity-5.32%-3.75%-0.85%

Analyst Ratings

This is a summary of current recommendations for Medtronic and Star Equity, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Medtronic031812.91
Star Equity0000N/A

Medtronic currently has a consensus target price of $124.2692, indicating a potential upside of 0.30%. Given Medtronic's higher possible upside, analysts plainly believe Medtronic is more favorable than Star Equity.

Valuation & Earnings

This table compares Medtronic and Star Equity's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Medtronic$28.91 billion5.78$4.79 billion$4.5926.99
Star Equity$114.18 million0.14$-4,630,000.00N/AN/A

Medtronic has higher revenue and earnings than Star Equity.

Risk & Volatility

Medtronic has a beta of 0.7, indicating that its stock price is 30% less volatile than the S&P 500. Comparatively, Star Equity has a beta of 0.24, indicating that its stock price is 76% less volatile than the S&P 500.

Institutional and Insider Ownership

79.2% of Medtronic shares are owned by institutional investors. Comparatively, 10.1% of Star Equity shares are owned by institutional investors. 0.5% of Medtronic shares are owned by company insiders. Comparatively, 12.5% of Star Equity shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Summary

Medtronic beats Star Equity on 12 of the 13 factors compared between the two stocks.

Varian Medical Systems (NYSE:VAR) and Star Equity (NASDAQ:STRR) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

Risk & Volatility

Varian Medical Systems has a beta of 1.06, indicating that its stock price is 6% more volatile than the S&P 500. Comparatively, Star Equity has a beta of 0.24, indicating that its stock price is 76% less volatile than the S&P 500.

Valuation and Earnings

This table compares Varian Medical Systems and Star Equity's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Varian Medical Systems$3.17 billion5.13$269.20 million$3.9145.29
Star Equity$114.18 million0.14$-4,630,000.00N/AN/A

Varian Medical Systems has higher revenue and earnings than Star Equity.

Institutional & Insider Ownership

87.0% of Varian Medical Systems shares are owned by institutional investors. Comparatively, 10.1% of Star Equity shares are owned by institutional investors. 0.8% of Varian Medical Systems shares are owned by insiders. Comparatively, 12.5% of Star Equity shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Profitability

This table compares Varian Medical Systems and Star Equity's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Varian Medical Systems8.50%18.45%8.08%
Star Equity-5.32%-3.75%-0.85%

Analyst Recommendations

This is a breakdown of recent recommendations for Varian Medical Systems and Star Equity, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Varian Medical Systems35001.63
Star Equity0000N/A

Varian Medical Systems presently has a consensus target price of $159.3571, indicating a potential downside of 10.00%. Given Varian Medical Systems' higher probable upside, equities research analysts clearly believe Varian Medical Systems is more favorable than Star Equity.

Summary

Varian Medical Systems beats Star Equity on 10 of the 11 factors compared between the two stocks.

Masimo (NASDAQ:MASI) and Star Equity (NASDAQ:STRR) are both medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, dividends and risk.

Insider and Institutional Ownership

81.6% of Masimo shares are owned by institutional investors. Comparatively, 10.1% of Star Equity shares are owned by institutional investors. 11.5% of Masimo shares are owned by insiders. Comparatively, 12.5% of Star Equity shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Risk and Volatility

Masimo has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500. Comparatively, Star Equity has a beta of 0.24, indicating that its stock price is 76% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of recent ratings and price targets for Masimo and Star Equity, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Masimo02502.71
Star Equity0000N/A

Masimo currently has a consensus price target of $272.20, indicating a potential upside of 13.63%. Given Masimo's higher possible upside, research analysts clearly believe Masimo is more favorable than Star Equity.

Earnings & Valuation

This table compares Masimo and Star Equity's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Masimo$937.84 million14.12$196.22 million$3.2274.39
Star Equity$114.18 million0.14$-4,630,000.00N/AN/A

Masimo has higher revenue and earnings than Star Equity.

Profitability

This table compares Masimo and Star Equity's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Masimo20.30%15.75%13.12%
Star Equity-5.32%-3.75%-0.85%

Summary

Masimo beats Star Equity on 11 of the 12 factors compared between the two stocks.

LivaNova (NASDAQ:LIVN) and Star Equity (NASDAQ:STRR) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, earnings, analyst recommendations, institutional ownership, profitability, valuation and dividends.

Volatility and Risk

LivaNova has a beta of 0.8, suggesting that its share price is 20% less volatile than the S&P 500. Comparatively, Star Equity has a beta of 0.24, suggesting that its share price is 76% less volatile than the S&P 500.

Insider & Institutional Ownership

89.1% of LivaNova shares are held by institutional investors. Comparatively, 10.1% of Star Equity shares are held by institutional investors. 0.5% of LivaNova shares are held by company insiders. Comparatively, 12.5% of Star Equity shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and target prices for LivaNova and Star Equity, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
LivaNova04202.33
Star Equity0000N/A

LivaNova presently has a consensus target price of $69.3333, suggesting a potential downside of 14.79%. Given LivaNova's higher probable upside, equities research analysts plainly believe LivaNova is more favorable than Star Equity.

Profitability

This table compares LivaNova and Star Equity's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
LivaNova-21.88%5.55%3.07%
Star Equity-5.32%-3.75%-0.85%

Earnings & Valuation

This table compares LivaNova and Star Equity's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LivaNova$1.08 billion3.65$-155,180,000.00$3.0826.42
Star Equity$114.18 million0.14$-4,630,000.00N/AN/A

Star Equity has lower revenue, but higher earnings than LivaNova.

Summary

LivaNova beats Star Equity on 8 of the 12 factors compared between the two stocks.

Star Equity (NASDAQ:STRR) and CONMED (NYSE:CNMD) are both multi-sector conglomerates companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends and risk.

Profitability

This table compares Star Equity and CONMED's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Star Equity-5.32%-3.75%-0.85%
CONMED0.04%9.48%3.75%

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Star Equity and CONMED, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Star Equity0000N/A
CONMED02402.67

CONMED has a consensus target price of $104.60, suggesting a potential downside of 19.82%. Given CONMED's higher probable upside, analysts clearly believe CONMED is more favorable than Star Equity.

Insider & Institutional Ownership

10.1% of Star Equity shares are owned by institutional investors. 12.5% of Star Equity shares are owned by company insiders. Comparatively, 5.4% of CONMED shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Risk and Volatility

Star Equity has a beta of 0.24, indicating that its stock price is 76% less volatile than the S&P 500. Comparatively, CONMED has a beta of 1.55, indicating that its stock price is 55% more volatile than the S&P 500.

Earnings & Valuation

This table compares Star Equity and CONMED's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Star Equity$114.18 million0.14$-4,630,000.00N/AN/A
CONMED$955.10 million3.95$28.62 million$2.6449.41

CONMED has higher revenue and earnings than Star Equity.

Summary

CONMED beats Star Equity on 9 of the 12 factors compared between the two stocks.

InMode (NASDAQ:INMD) and Star Equity (NASDAQ:STRR) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, valuation, earnings, institutional ownership, analyst recommendations and dividends.

Institutional & Insider Ownership

35.7% of InMode shares are owned by institutional investors. Comparatively, 10.1% of Star Equity shares are owned by institutional investors. 12.5% of Star Equity shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and price targets for InMode and Star Equity, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
InMode00403.00
Star Equity0000N/A

InMode presently has a consensus price target of $71.50, indicating a potential downside of 14.40%. Given InMode's higher possible upside, analysts clearly believe InMode is more favorable than Star Equity.

Valuation and Earnings

This table compares InMode and Star Equity's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
InMode$156.36 million17.08$61.15 million$1.6052.21
Star Equity$114.18 million0.14$-4,630,000.00N/AN/A

InMode has higher revenue and earnings than Star Equity.

Profitability

This table compares InMode and Star Equity's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
InMode32.57%28.56%24.14%
Star Equity-5.32%-3.75%-0.85%

Risk and Volatility

InMode has a beta of 1.95, meaning that its stock price is 95% more volatile than the S&P 500. Comparatively, Star Equity has a beta of 0.24, meaning that its stock price is 76% less volatile than the S&P 500.

Summary

InMode beats Star Equity on 11 of the 12 factors compared between the two stocks.


Star Equity Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Medtronic logo
MDT
Medtronic
2.7$123.90-0.2%$166.66 billion$28.91 billion47.29
Varian Medical Systems logo
VAR
Varian Medical Systems
1.3$177.07-0.0%$16.27 billion$3.17 billion60.43
Masimo logo
MASI
Masimo
1.6$239.55-0.1%$13.22 billion$937.84 million62.22Insider Selling
LivaNova logo
LIVN
LivaNova
1.5$81.37-0.8%$3.99 billion$1.08 billion-18.92Analyst Report
News Coverage
CNMD
CONMED
1.6$130.45-1.1%$3.82 billion$955.10 million-3,261.25
InMode logo
INMD
InMode
1.5$83.53-0.4%$2.68 billion$156.36 million60.09Analyst Downgrade
Outset Medical logo
OM
Outset Medical
1.0$54.50-0.1%$2.34 billionN/A0.00Analyst Upgrade
BioLife Solutions logo
BLFS
BioLife Solutions
2.1$33.59-3.2%$1.16 billion$27.37 million-46.01Insider Selling
Increase in Short Interest
NTUS
Natus Medical
1.1$28.63-4.5%$926.45 million$495.52 million-52.05
AxoGen logo
AXGN
AxoGen
1.5$19.42-1.2%$801.17 million$106.71 million-30.83News Coverage
TransMedics Group logo
TMDX
TransMedics Group
1.6$29.13-0.7%$792.09 million$23.60 million-20.81Increase in Short Interest
Gap Down
ViewRay logo
VRAY
ViewRay
1.3$4.43-2.9%$691.44 million$87.78 million-4.98
Cutera logo
CUTR
Cutera
1.3$30.78-1.6%$556.07 million$181.71 million-17.01
Zynex logo
ZYXI
Zynex
1.8$15.19-1.1%$523.87 million$45.47 million46.03
Edap Tms logo
EDAP
Edap Tms
1.3$9.06-1.4%$267.82 million$50.23 million-151.00Increase in Short Interest
Second Sight Medical Products logo
EYES
Second Sight Medical Products
0.8$8.24-1.8%$195.07 million$3.38 million-4.31Decrease in Short Interest
BioSig Technologies logo
BSGM
BioSig Technologies
0.5$4.21-2.6%$137.33 millionN/A0.00News Coverage
FONR
FONAR
1.1$17.98-0.1%$117.78 million$85.69 million16.96
IRIDEX logo
IRIX
IRIDEX
0.9$7.41-1.2%$113.61 million$43.45 million-13.47
Soleno Therapeutics logo
SLNO
Soleno Therapeutics
1.9$1.22-2.5%$94.87 millionN/A-1.61Increase in Short Interest
ENDRA Life Sciences logo
NDRA
ENDRA Life Sciences
0.6$2.28-3.5%$94.85 million$10,000.00-1.24Analyst Upgrade
Increase in Short Interest
electroCore logo
ECOR
electroCore
1.4$1.82-1.1%$89.20 million$2.39 million-2.30Decrease in Short Interest
Helius Medical Technologies logo
HSDT
Helius Medical Technologies
1.5$17.56-0.7%$40.28 million$1.50 million-1.00Increase in Short Interest
CHF Solutions logo
CHFS
CHF Solutions
1.7$5.33-1.7%$31.63 million$5.51 million-0.11High Trading Volume
Increase in Short Interest
Viveve Medical logo
VIVE
Viveve Medical
0.9$3.01-0.3%$31.03 million$6.57 million-0.01
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.